Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma [0.03%]
抗GD2免疫疗法达妥昔单抗β治疗高危复发或难治性神经母细胞瘤的疗效和安全性评估研究
Aleksandra Wieczorek,Katarzyna Śladowska,Holger N Lode
Aleksandra Wieczorek
Background: High-risk neuroblastoma (HR-NB) is associated with a poor prognosis. Standard first-line maintenance therapy with anti-disialoganglioside 2 (GD2) monoclonal antibodies, such as dinutuximab beta, has improved s...
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy [0.03%]
放射配体治疗前列腺癌患者的PSMA PET影像检查：前列腺癌转移性去势抵抗期
Phillip H Kuo,Jeremie Calais,Mike Crosby
Phillip H Kuo
Despite an evolving treatment landscape for people with metastatic castration-resistant prostate cancer, prognosis for this patient population remains poor. Prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging ...
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation [0.03%]
奥拉帕尼单药或联合阿比特龙治疗携带BRCA突变的转移性去势抵抗性前列腺癌 (mCRPC) 患者
Fred Saad,Andrew J Armstrong,Neal Shore et al.
Fred Saad et al.
Treatment strategies to improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) are evolving. Of particular interest are therapies that target DNA damage responses in tumor cells by inhibiting poly(ADP-ribo...
Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective [0.03%]
高效利库肽联合雄激素受体途径抑制剂治疗转移性前列腺癌的临床思考
Tomas Buchler
Tomas Buchler
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, has been established as an effective androgen deprivation therapy (ADT) for advanced prostate cancer, offering advantages over traditional GnRH agonists. The comb...
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma [0.03%]
成人软组织肉瘤免疫治疗抵抗的潜在机制
Zaina S Kret,Ryan J Sweder,Raphael Pollock et al.
Zaina S Kret et al.
Soft-tissue sarcomas represent a diverse group of rare malignancies originating from mesenchymal tissue, accounting for less than 1% of adult cancers in the USA. With over 13,000 new cases and around 5350 deaths annually, patients with meta...
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure [0.03%]
表皮生长因子受体突变亚型对表皮生长因子受体酪氨酸激酶抑制剂失败后非小细胞肺癌化疗免疫治疗和单纯化疗疗效的影响
Kenji Morimoto,Tadaaki Yamada,Naoki Furuya et al.
Kenji Morimoto et al.
Background: The efficacy of immune checkpoint inhibitor (ICI) monotherapy on non-small-cell lung cancer (NSCLC) varies by epidermal growth factor receptor (EGFR) mutation subtypes. However, the impact of these subtypes on...
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials [0.03%]
罕见HRR基因变异预测PARP抑制剂治疗转移性去势抵抗性前列腺癌疗效的 meta 分析：基于随机对照试验的分析
Giada Pinterpe,Fortuna Migliaccio,Chiara Ciccarese et al.
Giada Pinterpe et al.
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA1/2 mutations show significant responses to poly-ADP ribose polymerase inhibitors (PARPi), while the efficacy of these agents in patien...
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment [0.03%]
抗体药物偶联物在癌症治疗中的抗性机制探讨
Gloria Lalli,Ilaria Sabatucci,Mariachiara Paderno et al.
Gloria Lalli et al.
Antibody-drug conjugates (ADCs) are an innovative approach in cancer therapy, combining the specificity of monoclonal antibodies (mAb) with the cytotoxic effect of chemotherapy agents. Despite the remarkable efficacy demonstrated in clinica...
Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis [0.03%]
Pemigatinib治疗携带FGF受体融合或重排的晚期胆管癌的有效性和毒性：系统评价和 meta 分析
Erman Akkus,Hatime Arzu Yasar,Lorenza Rimassa et al.
Erman Akkus et al.
Background: The efficacy and safety of pemigatinib in advanced cholangiocarcinoma (aCCA) were presented in phase I-II trials and retrospective reports, with small sample sizes and variable results. ...
Zachary A Yochum,David A Braun
Zachary A Yochum
The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immune chec...